Why the study?
Both transfemoral and transapical approaches to TAVR are widely adopted, but comparisons of their performance are limited to a few studies with controversial results.
Does transfemoral TAVR reduce mortality and morbidity compared to transapical TAVR in patients with aortic disease?
Does transfemoral TAVR reduce mortality and morbidity compared to transapical TAVR in patients with aortic disease?
Transfemoral TAVR is associated with lower early mortality, bleeding, and acute kidney injury compared to transapical TAVR, though it carries a higher risk of vascular complications and pacemaker implantation.
Answers are grounded in this paper and cite their sources.
TF-TAVR lowers mortality versus TA-TAVR; reinforces TF preference in eligible patients and guides future access-site optimization research.
Background: Transcatheter aortic valve replacement (TAVR) has gained increasing acceptance for patients with aortic disease. Both transfemoral (TF-TAVR) and transapical (TA-TAVR) approach were widely adopted while their performances are limited to a few studies with controversial results. This meta-analysis aimed to compare the mortality and morbidity of complications between TF- versus TA-TAVR based on the latest data. Methods: Electronic databases were searched from January 2005 to December 2019. RCTs and observational studies comparing the outcomes between TF-TAVR versus TA-TAVR patients were included. Heterogeneity assumption was assessed by an I2 test. The pooled odds ratios(OR) or mean differences with corresponding 95% confidence intervals (CI) were used to evaluate the difference for each end point using a fixed-effect model or random-effect model based on I2 test. Results: The meta-analysis included 1 RCT and 18 observational studies, enrolling 12,953 patients (TF-TAVR, n=8,649 and TA-TAVR, n=4,304). Compared with TA-TAVR, TF-TAVR patients showed significantly lower rate of postoperative in-hospital death (OR=0.63, 95%CI 0.54-0.74, P<0.001) and 1-year death(OR=0.53, 95%CI 0.41-0.69, P<0.001). Incidence of major bleeding and acute kidney injury were lower, whereas those of permanent pacemaker and major vascular complication were higher in TF-TAVR patients. There were no significant differences between TF-TAVR versus TA-TAVR for stroke and mid-term mortality.Conclusions: There were fewer early deaths in patients with transfemoral approach, whereas the number of mid-term deaths and stroke was not significantly different between two approaches. TF-TAVR was associated with lower risk of bleeding, acute kidney injury as well as shorter in-hospital stay, but higher incidence of vascular complication and permanent pacemaker implantation.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2020) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: